Advancement of mammalian CYP450s expression in E.coli

Abstract

Abstract: Cytochrome P450(CYP450) is one of most important enzymes to metabolize endogenous and exogenous substrates in vivo.With the development of molecular biology and recombinant technology, the manipulating and heterogeneous expression of CYP450 cDNA become possible.Many kinds of heterogeneous expression systems have been generally operated nowadays, of which there are advantages and disadvantages respectively.It is usual to express mammalian CYP450s using E.coli as host in Lab, but different protein production and enzyme activity are brought by different expression systems and purification procedures.The present application of different expression modes using E.coli for mammalian CYP450 cDNA will be introduced as well as their advantages and the limits respectively.

Key words: heterogeneous expression, cytochrome P450, E.coli

CLC Number:

R968

ZHANG Che, ZHANG Zhi-quan, ZHOU Hong-hao. Advancement of mammalian CYP450s expression in E.coli[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(9): 970-973.

References

1 Zhu LQ, Lou JS.Resent studies on cytochrome P450 and drug metabolism [J].Chin J Clin Pharmacol Ther, 2004;9:1081-1084.
2 Friedberg T, Pritchard MP, BanderaM, et al.Merits and limitations of recombinant models for the study of human p450-mediated drug metabolism and toxicity :an intra-laboratory comparison [J].Drug Metab Rev, 1999;31:523-544.
3 Sandhu P, Baba T, Guenguerich FP.Expression of modified cytochrome P450 2C10 (2C9) in Echerichia coli, purification, and reconstitution of catalytic activity [J].Arch Biochem Biophys, 1993;306:443-450.
4 Larson JR, CoonMJ, Porter TD.Alcohol-inducible cytochrome P-450IIE1 lacking the hydrophobic NH2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli [J].J Biol Chem, 1991;266 :7321-7324.
5 Larson JR, Coon MJ, Porter TD.Purification and properties of a shortened form of cytochrome P-450 2E1:Deletion of the NH2-terminal membrane-insertion signal peptide does not alter the catalytic activities [J].Proc Nati Acad Sci USA, 1991;88: 9141-9145.
6 Li YC, Chiang JY.The expression of a catalytically active cholesterol 7α-hydroxylase cytochrome P450 in Escherichia coli [J]. J Biol Chem, 1991;266:19186-19191.
7 Loomanl AC, Bodlaender J, Comstock LJ, et al.Influence of the codon following the AUG initiation codon on the expression of a modified lacZ gene in Escherichia coli [J].EMBO J, 1987; 6:2489-2492.
8 Barnes HJ, Arlotto MP, Waterman MR.Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli [J].Prc Natl Acad Sci USA, 1991;88:5597-5601.
9 Shet MS, Fisher CW, Ariotto MP, et al.Purification and enzymatic properties of a recombinant fusion protein expressed in Escherichia coli containing the domains of bovine P450 17A1 and rat NADPH-P450 reductase [J].Arch Biochem Biophys, 1993; 311:402-417.
10 Guo Z, Gillam EMJ, Ohmod S, et al.Expression of modified human eytochrome P450 1AI in Escherichia coli :effects of 5'substitution, stabilization, purification, spectral characterization and catalytic properties [J].Arch Biochem Biophys, 1994; 312:436-446.
11 Sandhu P,Guo Z, Baba T, et al.Expression of modified human cytochrome P450 IA2 in Escherichla coil:stabilization, purification, spectral characterization, and catalytic activities of the enzyme [J].Arch Biochem Biophys, 1994;309:168-177.
12 Kranendonk M, Fisher CW, Roda R, et al.Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 :comparison of three types expression systems [J].Mutat Res, 1999;439 :287-300.
13 Kranendonk M, Carreira F, Theisen P, et al.Escherichia coli · 972 · Chin J Clin Pharmacol Ther 2007 Sep;12(9) MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5:catalytic activities and mutagenicity studies [J].Mutat Res, 1999;441:73-83.
14 Gillam EMJ, Baba T, Kim B-R, et al.Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconsitition of the enzyme [J].Arch Biochem Biophys, 1993;305 :123-131.
15 Gillam EM, Wunsch RM, Ueng YF, et al.Expression of cytochrome P450 3A7 in Escheriachia coli :ffects of 5'-modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase [J].Arch Biochem Biophys, 1997;346:81-90.
16 Palmer CNA, Richardson TH, Griffin KJ, et al.Characterization of a cDNA coding a human kidney, cytochrome P-450 4A fatty acid omega-hydroxylase and the cognate enzyme expressed in Escherichia coli [J].Biochim Biophy s Acre Gene Struct, 1993; 1172 :161-166.
17 Andersen JF, Utermohlen JG, Feyereisen R.Expression of house fly CYP6A1 and NADPH.cytochrome P450 reductase in Escherichia coli and reconstitution of an insecticide-metabolizing P450 system [J].Biochemistry, 1994;33 :2171-2177.
18 Fisher CW, Caudle DL, Martin-Wixtrom C, et al.High-level expression of functional human cytochrome P450 1A2 in Escherichia coli [J].FASEB J, 1992;6:759-764.
19 Shet MS, Fisher CW, Holmans PL, et al.Human cytochrome P450 3A4:Enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase [J].Proc Natl Acad Sci USA, 1993;90:11748-11752.
20 Shet MS, Fisher CW, Ariotto MP, et al.Purification and enzymatic properties of a recombinant fusion protein expressed in Escherichia coli containing the domains of bovine P450 17A1 and rat NADPH-P450 reductase [J].Arch Biochem Biophys, 1994;377:402-417.
21 Blake JAR, Pritchard M, Ding SH, et al.Co-expression of a human P450 (CYP3A4) and P450 reductase generates a highly functional mono-oxygenase system in Escherichia coli [J].FEBS Lett, 1996;397:210-214.
22 Parikh A, Guengerich FP.Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2 :rat NADPH-cytochrome P450 reductase fusion protein [J].Protein Expr Purif, 1997;9:346-354.
23 Kamataki T, Fujita K, Nakayama K, et al.Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives:application of genetically engineered Salmonella expressing human CYP [J].Drug Metab Rev, 2002;34:667-676.
24 Gillam EMJ, Baba T, Kim BR, et al.Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme [J].Arch Biochem Biophys, 1993;305:121-131.
25 Zhuang X, Zhang H.Identification, characterization of levoglucosan kinase, and cloning and expression of levoglucosan kinase cDNA from Aspergillus niger CBX-209 in Escherichia coli [J]. Protein Expr Purif, 2002;26:71-81.
26 Domanski TL, Finta C, Halpert JR, et al.cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450 [J].Mol Pharmacol, 2001;59 :386-392.
27 Zhou JQ, Tang ZQ.Cytochrome P450 directed prodrug activation therapy in research of cancer enzymology [J].J Chin Pharmace Sci, 2005;14 :1-9.
28 Friedberg I.Recombinant in vitro tools to predict drug metabolism and safety [J].Pharm Sci Technolo Today, 2000;3:99-105.

[1]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[2]	WU Yi, FANG Fang, CHEN Ying, Fan Junwei. Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639.
[3]	WU Qiaoyu, YUAN Hong, LU Yao. Evaluation of the effects of resveratrol on the activity human cytochrome P450 through combined probe method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 426-432.
[4]	WU Maofeng, LIU Chang, DAI Huihui, MAI Zhangfeng, HUANG Danli, MIAO Jingwei, LIU Lizhong, FANG Yi. Preliminary association of individual different plasma pazopanib concentration with CYP3A4 gene polymorphism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1376-1380.
[5]	PENG Qiuju, YAN Huacheng, SHI Lei. Advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 477-480.
[6]	ZHANG Peiyu, REN Jing, ZHI Wenqian, LIU Chengming, GAO Na. Inhibition of CYP450 activity by honokiol and other four components of Chinese traditionalmedicine in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 922-926.
[7]	YIN Shuo, YU Yue, GUO Xing-lei, LIU Gao-feng. Effects of traditional Chinese medicine on the role of warfarin and the mechanisms [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 327-334.
[8]	LIU Li-ya, HAN Yong-long, YU Qi, ZHU Jin-hui, GUO Cheng. In vitro inhibition of 4 anti-tumor traditional Chinese medicine injections on activities of 7 main cytochrome P450s in human liver microsome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 522-527.
[9]	LIU Jun, LUAN Jia-jie, XU Wen-ke, ZHU Yan-hong, WANG Wei-ping, ZHANG Da-fa. Study on warfarin individual dosage model based on clinical factors and gene in Chinese Han population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 284-290.
[10]	ZHANG Ran-ran, YANG Guo-ping, JING Ning-ning, HUANG Jie, HUANG Lu, WANG Yan. Effects of food on Cytochrome P450 drug metabolic enzymes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 200-205.
[11]	JIA Yuan-wei, PENG Ying, SUN Jian-guo, XIE Hai-tang, CHU Ji-ru, SHEN Jie. “N-in-One Cocktail” method to evaluate inhibition effects of 4-hydroxylmethylphenyl-O-β-D-pyranosyl alloside on CYP450 enzymes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1371-1375.
[12]	LV Pei-yu, YUAN Hong, ZHOU Hong-hao, OUYANG Dong-sheng. Genetic variation of cytochrome P450 oxidase and personalized medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1281-1287.
[13]	HUANG Lu, YANG Guo-ping. Progress on influence of cytochrome P450 oxidoreductase polymorphisms on cytochrome P450 monoxyfenases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 818-823.
[14]	WU Chun, GAO Jing-wen, YAO Mei-cun, HOU Xue-ying, ZHOU Yu-ting, DENG Xue-jiao, LIAO Qiong-feng, XIE Zhi-yong. Effect of natural borneol on the activities of cytochrome p450 isoforms in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 121-127.
[15]	OUYANG Dong-Sheng, SHUAI Fang-Wen, ZHOU Hong-Hao. Research progress on pharmaceutical necessities affecting the cytochrome P450 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 99-102.